Marlowe plc (LON:MRL – Get Free Report) insider Peter M. R. Gaze bought 15,000 shares of Marlowe stock in a transaction on Friday, September 27th. The shares were purchased at an average cost of GBX 309 ($4.13) per share, with a total value of £46,350 ($61,998.39).
Marlowe Stock Performance
Shares of MRL opened at GBX 328.83 ($4.40) on Wednesday. The firm has a market capitalization of £289.37 million, a PE ratio of -2,344.64 and a beta of 0.44. The company has a quick ratio of 0.80, a current ratio of 1.24 and a debt-to-equity ratio of 58.99. The firm has a 50-day moving average price of GBX 436.14 and a 200 day moving average price of GBX 482.13. Marlowe plc has a 52-week low of GBX 220 ($2.94) and a 52-week high of GBX 620 ($8.29).
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on MRL shares. Royal Bank of Canada reiterated an “outperform” rating and set a GBX 690 ($9.23) price objective on shares of Marlowe in a research report on Thursday, August 1st. Berenberg Bank reaffirmed a “buy” rating and set a GBX 710 ($9.50) target price on shares of Marlowe in a research note on Wednesday, August 21st.
Marlowe Company Profile
Marlowe plc provides compliance services and software in the United Kingdom. The company operates in two segments, Governance, Risk and Compliance; and Testing, and Inspection and Certification. It offers health and safety consultancy, risk and audit assessments, environmental, contractor management, and training services; and health and safety support services.
Recommended Stories
- Five stocks we like better than Marlowe
- How to Choose Top Rated Stocks
- Why Lennar Stock Could Be the Best Play in the Housing Market
- What Are the FAANG Stocks and Are They Good Investments?
- 2 Energy Stocks Fueling the AI Datacenter Boom
- How to Invest in Small Cap Stocks
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Marlowe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marlowe and related companies with MarketBeat.com's FREE daily email newsletter.